K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$268.60
Prev. Close
$263.36
Prev. Day's Range
$263.13 - $268.60
52W Range
$151.01 - $269.43
Trading Volume
5.187M
MC
$643.305B
P/E Ratio
30.0x
EPS
$8.90
Company Overview
NYSE
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
HeadquartersONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, UNITED STATES, 08933
Johnson & Johnson (ticker: JNJ) operates in the healthcare sector, focusing on pharmaceuticals, medical devices, and consumer health products. It generates revenue through innovative drug therapies, surgical products, and everyday healthcare items like baby care and personal hygiene products. Its diversified portfolio and global presence have made it a leader in the industry.
Johnson & Johnson’s growth opportunities primarily lie in the development of cutting-edge pharmaceuticals, especially in oncology and immunology, and advancements in medical technology. Expansion into emerging markets and the aging global population provide further potential. However, growth can be influenced by competitive pressures and regulatory hurdles.
Yes, Johnson & Johnson is known for paying consistent dividends and has an extensive history as a dividend aristocrat. It is considered attractive to income-focused investors due to its reliable dividend growth, supported by stable cash flow. Investors should note that dividends are subject to company performance and market conditions.
Investors should consider risks such as litigation and liability claims, particularly regarding product safety. Regulatory pressures and changes to healthcare policies could impact operations. Additionally, competition in the pharmaceutical and medical device sectors might influence future growth and profitability.
Johnson & Johnson faces competition from other global healthcare companies like Pfizer, Merck, Abbott Laboratories, and Procter & Gamble. Each competes in pharmaceuticals, medical devices, or consumer health, and innovation in these areas is a key driver of market share.
Johnson & Johnson is often viewed as a defensive stock due to its steady earnings and diversified portfolio. Its valuation typically reflects a premium due to its reputation and consistent financial performance. Investors should assess how external factors, such as economic cycles, health crises, or interest rates, affect valuation over time.
Johnson & Johnson operates across the pharmaceutical, medical devices, and consumer health industries. Its three-sector model provides diversification that helps mitigate risks from individual business lines. This unique structure positions JNJ as a stable player in the volatile healthcare sector.
Johnson & Johnson manages product recalls through stringent safety protocols and compliance standards. Despite these efforts, legal challenges, including high-profile lawsuits, can affect its financial position and reputation. Investors should monitor company statements and regulatory developments related to litigation.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
